secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
CIK:        0001979414
Form:       8-K
Filed at:   2026-06-23T21:00:27+00:00
Accession:  0001829126-26-006773
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeOnc receives UAE IND approval for NEO100; Phase 2a data expected by end of July 2026
--------------------------------------------------------------------------------

- UAE DOH granted IND status for NEO100 across adult Phase 1-2 and pediatric studies for recurrent gliomas.
- NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations.
- Top-line Phase 2a data from fully enrolled NEO100-01 trial expected by end of July 2026.
- Authorization follows recent UAE IND clearance for NEO212, expanding development footprint.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1979414/000182912626006773/0001829126-26-006773-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1979414/000182912626006773/neonctechnologies_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-26-006773

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer